Genomics4S

The ability to reduce the burden of genetic disease is one of the most compelling promises of genomic medicine. But the path forward for embryo selection and gene editing is not purely technical; it demands rigorous evaluation of scientific evidence, sustained ethical reflection, and broad public consensus.

The global AI in clinical trials market, valued at US$1.20 billion in 2023, is projected to grow at a 12.4% annually, reaching US$2.74 billion by 2030. As AI reshapes how patients are identified, matched, and enrolled in clinical research, regulatory frameworks must evolve to address the structural diversity, data flows, and ethical risks embedded in these emerging platforms.

AI systems require public data and cooperation to function responsibly, yet people won’t share their data unless they already trust the systems collecting and utilizing it. Solving this paradox must be a policy priority for developers and the Canadian government.

By focusing on fairness, accountability, and transparency, we can guarantee that AI-driven innovations in clinical trials improve—rather...